Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM57 vs HRIG in combination with rabies vaccine in children and adolescents
ChiCTR2100050124Phase 3Not yet recruiting
- Sponsor
- Yunnan Center for Disease Control and Prevention
- Start
- Aug 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in rabies comparing NM57 + human rabies vaccine with HRIG + human rabies vaccine (2 arms). Primary endpoint: neutralizing antibody activity. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
ormutivimabrabies immune globulin (human)human rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2100050124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050124.